Friedreich Ataxia — Research Summary
Printed from RareWays (rareways.com.au) on 8 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Mitochondrial iron overload is associated with lysosomal dysfunction-mediated mitophagy impairment in the heart of Friedreich's ataxia.
Jee Eunbin et al. — Mitochondrion (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41628678/
- 2.
Targeting the Keap1-Nrf2 Axis in COPD: Comparative analysis of electrophilic and peptide-based Nrf2 activators in airway and immune cells.
Roger Inés et al. — European journal of pharmacology (28 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41786067/
- 3.
Fronto-Cerebellar Connectivity Disruptions and Functional Reorganization in Friedreich's Ataxia: A Structural and Resting-State fMRI Study.
Dadsena Ravi et al. — NeuroImage (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41865916/
- 4.
Advanced Heart Failure in Friedreich's Ataxia: A Story of Challenges, Opportunities, and Hope.
Miyashita Satoshi et al. — JACC. Case reports (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41860485/
- 5.
The multifaceted nature of Friedreich ataxia: strategies for comprehensive patient care.
Raza Muhammad Liaquat et al. — Neurodegenerative disease management (17 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41844425/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Recruiting — Phase 1 — Design Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06874010
- 2.
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
Recruiting — Phase 3 — Biogen
https://clinicaltrials.gov/study/NCT06953583
- 3.
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Recruiting — Friedreich's Ataxia Research Alliance
https://clinicaltrials.gov/study/NCT06016946
- 4.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Friedreich Ataxia
Friedreich ataxia is a progressive genetic condition that damages the nervous system and heart, causing loss of coordination, balance problems, and heart disease. It is the most common inherited ataxia. Symptoms usually begin in childhood or adolescence. The first approved treatment, omaveloxolone, reached approval in 2023.
Most Recent Research
Friedreich's ataxia (FRDA) is a rare disease caused by deficiency of frataxin, a mitochondrial protein essential for iron-sulfur cluster assembly and iron homeostasis. In addition to neurological symptoms, cardiac dysfunction is common and represents a major cause of premature death in FRDA. Although iron overload has been suggested as a major player for FRDA-related cardiomyopathy, its underlying mechanisms remain unclear. Using heart-specific frataxin deficient mice, we observed that FRDA-related cardiac hypertrophy is accompanied by mitochondrial iron overload. Transmission electron microscopy (TEM) revealed iron aggregates within cardiac mitochondria, whose ultrastructure was severely altered. Along with the iron deposits and structural abnormalities, mitochondrial respiration was markedly impaired in FRDA hearts, despite the absence of increased oxidative stress. Notably, although dysfunctional mitochondria accumulate in parallel with enhanced mitochondrial biogenesis, the clearance of damaged or dysfunctional mitochondria (i.e., mitophagy) is disrupted, as evidenced by excessive accumulation of p62 and Parkin proteins. The lysosomal system, which plays a central role for mitochondrial turnover, appears to be dysregulated via the mTOR-TFEB axis. Hyperactivation mTOR inhibits lysosomal biogenesis and function, although lysosomal content remains unchanged. Collectively, our study provides mechanistic insight into the role of mitochondrial iron aggregates in the pathogenesis of FRDA-related cardiomyopathy and suggests a potential contribution of lysosomal dysfunction to impaired mitochondrial quality control in the context of cardiac frataxin deficiency.
Common Questions
What is Friedreich Ataxia?
Friedreich ataxia is a progressive genetic condition that damages the nervous system and heart, causing loss of coordination, balance problems, and heart disease. It is the most common inherited ataxia. Symptoms usually begin in childhood or adolescence. The first approved treatment, omaveloxolone, reached approval in 2023.
How many clinical trials are available for Friedreich Ataxia?
RareWays currently indexes 93 clinical trials for Friedreich Ataxia, of which 17 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Friedreich Ataxia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Friedreich Ataxia.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.